| Year |
Citation |
Score |
| 2012 |
Henderson MC, Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Frontiers in Oncology. 2: 38. PMID 22649786 DOI: 10.3389/fonc.2012.00038 |
0.302 |
|
| 2011 |
Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO. High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells. Molecular Cancer Research : McR. 9: 724-32. PMID 21536687 DOI: 10.1158/1541-7786.MCR-10-0436 |
0.501 |
|
| 2011 |
Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S. NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. Plos One. 6: e18306. PMID 21483694 DOI: 10.1371/Journal.Pone.0018306 |
0.328 |
|
| 2009 |
Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. The Journal of Pharmacology and Experimental Therapeutics. 331: 636-47. PMID 19657049 DOI: 10.1124/Jpet.109.156406 |
0.407 |
|
| 2009 |
Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. Journal of Translational Medicine. 7: 43. PMID 19519883 DOI: 10.1186/1479-5876-7-43 |
0.452 |
|
| 2009 |
Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD. UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics. 8: 36-44. PMID 19139111 DOI: 10.1158/1535-7163.Mct-08-0789 |
0.404 |
|
| Show low-probability matches. |